HC Wainwright reaffirmed their buy rating on shares of Immix Biopharma (NASDAQ:IMMX - Free Report) in a research note issued to investors on Monday morning,Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock.
Immix Biopharma Price Performance
Shares of NASDAQ IMMX traded down $0.05 during trading on Monday, reaching $2.30. 91,513 shares of the stock traded hands, compared to its average volume of 83,871. The company has a 50-day moving average of $1.98 and a 200-day moving average of $1.94. Immix Biopharma has a 52-week low of $1.26 and a 52-week high of $6.87. The stock has a market capitalization of $63.27 million, a P/E ratio of -2.71 and a beta of 0.27.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.08). Analysts expect that Immix Biopharma will post -0.64 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Immix Biopharma
An institutional investor recently bought a new position in Immix Biopharma stock. Invst LLC acquired a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 27,000 shares of the company's stock, valued at approximately $57,000. Invst LLC owned approximately 0.10% of Immix Biopharma as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 11.26% of the company's stock.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Recommended Stories
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
